Publications:

PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.

British Journal Of Cancer

Shi, Qiyun Q; Xuhong, Juncheng J; Luo, Tao T; Ge, Jia J; Liu, Feng F; Lan, Yang Y; Chen, Qingqiu Q; Tang, Peng P; Fan, Linjun L; Chen, Li L; Liang, Yan Y; Wang, Minghao M; Hu, Ying Y; Zhang, Yi Y; Bian, Xiuwu X; Qi, Xiaowei X; Jiang, Jun J

Publication Date: 2022-11-02

Variant appearance in text: ERBB2: E1168K

PubMed Link: 36323880

Variant Present in the following documents:

• Main text
• 41416_2022_Article_2021.pdf

View BVdb publication page